Clinical trials: Refractory Acute Leukemia
Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome
Multi-antigen Specific CD8+ T Cells With Decitabine and Lymphodepleting Chemotherapy for the Treatment of Patients With Relapsed or Refractory AML or MDS Following an Allogeneic Hematopoietic Cell Transplantation From a Matched Donor
This phase I trial tests the safety, side effects and best dose of NEXI-001 when given with decitabine and lymphodepleting chemotherapy in treating patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that…
- Conditions
- Recurrent Acute Myeloid Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Acute Myeloid Leukemia, Refractory Myelodysplastic Syndrome
- Trial name
- NCT06572631
- Testing
- Allogeneic CD8+ Leukemia-associated Antigens Specific T Cells NEXI-001, Biospecimen Collection, Bone Marrow Aspiration
- Volunteers
- healthy volunteers welcome
- Sponsor
- City of Hope Medical Center
Acute Myeloid Leukemia in Children
Individualized Treatment of Pediatric R/R AML Based on Transcriptomic Profile and in Vitro Drug Sensitivity Test
Acute myeloid leukemia (AML) accounts for about 15% to 20% of childhood leukemia, but the death rate accounts for about 50%. About 20-30% of children with AML did not achieve complete response (CR) after 2 induction treatments…
- Trial name
- NCT06233526
- Testing
- Chemotherapy regiments based on the transcriptomic profile and in vitro drug sensitivity test
- Where
- China
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- The Children's Hospital of Zhejiang University School of Medicine